8-K - InMed Pharmaceuticals Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

InMed Pharmaceuticals Inc. received Nasdaq notice of non-compliance with the $1.00 minimum bid price rule, granting 180 calendar days to regain compliance with no immediate impact on trading under symbol INM.

Key Takeaways

1Received Nasdaq notice on March 27, 2026, for closing bid price below $1.00 over 30 consecutive trading days from February 11 to March 26, 2026.

2Has 180 calendar days to cure by achieving $1.00+ closing price for 10 consecutive business days.

3Shares continue trading on Nasdaq Capital Market under 'INM' with no immediate listing impact.

4May qualify for additional 180-day period if meeting other standards and notifying intent to cure, possibly via reverse stock split.

5Failure to comply risks delisting notice, appeal option with automatic trading suspension during appeal.

6Company intends to monitor share price and explore options to regain compliance.

Current Report Details

Event Type

Delisting

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.** On March 27, 2026, InMed Pharmaceuticals Inc. (the "Compa

Delisting

$1.00

9.01

.** **Financial Statements and Exhibits. ** Exhibit No.: 99.1 | Description: Press Release Exhibit No.: 104 | Description: Cover Page Interactive Data File (emb

Exhibits Only

Source Document

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1